Ark Genomic Revolution UCITS ETF (LON:ARKG)

Assets	81.92M
Expense Ratio	0.79%
PE Ratio	n/a
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	+86.63%

Volume	20,722
Open	9.93
Previous Close	9.86
Day's Range	9.75 - 9.93
52-Week Low	4.68
52-Week High	9.93
Beta	1.49
Holdings	32
Inception Date	Apr 12, 2024

About ARKG

The investment objective of the Fund is to generate long term capital growth (5 years or more)

• Asset Class: Equity
• Category: Theme
• Stock Exchange: London Stock Exchange
• Ticker Symbol: ARKG
• Provider: ARK

Performance

ARKG had a total return of 86.63% in the past year, including dividends. Since the fund's inception, the average annual return has been 39.20%.

Top 10 Holdings

58.93% of assets

Name	Symbol	Weight
Twist Bioscience Corporation	TWST	9.72%
Tempus AI, Inc.	TEM	9.22%
10x Genomics, Inc.	TXG	7.41%
CRISPR Therapeutics AG	CRSP	5.53%
Absci Corporation	ABSI	4.89%
Natera, Inc.	NTRA	4.61%
CareDx, Inc.	CDNA	4.61%
Illumina, Inc.	ILMN	4.50%
Personalis, Inc.	PSNL	4.46%
Eli Lilly and Company	LLY	3.98%

Data Sources: S&P Global Market Intelligence, Financial Modeling Prep, and more

Historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error